Corvus Pharmaceuticals
Develops immune-disease and cancer therapies centered on soquelitinib.
Something off on this page? Send us feedback.
Profile
Develops clinical-stage therapies for immune diseases and cancer, led by the oral ITK inhibitor soquelitinib. The pipeline also includes ciforadenant and mupadolimab, with Greater China rights held through Angel Pharmaceuticals and no product-sales revenue.
Develops clinical-stage therapies for immune diseases and cancer around immune-modulation biology. Soquelitinib is the lead program, an oral investigational ITK inhibitor being advanced in relapsed T-cell lymphomas and inflammatory diseases such as atopic dermatitis.
Ciforadenant targets adenosine A2A receptor signaling in the tumor microenvironment, while mupadolimab is an anti-CD73 antibody tied to adenosine production and B-cell binding. The portfolio remains investigational, with no approved products or product-sales revenue.
Based in South San Francisco, the company owns worldwide rights outside Greater China, where Angel Pharmaceuticals develops and commercializes the same core candidates. Its business depends on clinical-trial execution, regulatory approval, intellectual-property protection, and continued financing before commercial revenue can begin.
Company facts
Key statistics
Year to date +93.2% · Average volume (30d) 758.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Apr 17, 2026 | Goldman Sachs | Target | $40 | ||
| Jan 29, 2026 | Mizuho Securities | Target | $20 | $30 | |
| Jan 22, 2026 | Jefferies | Reiterate | Buy | $13 | $42 |
| Jan 21, 2026 | Oppenheimer | Reiterate | Outperform | $7 | $32 |
| Jan 20, 2026 | Barclays | Target | $16 | $28 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.16 | −$0.19 | −19.4% | — | — | — | +0.43% |
| May 7, 2026Q1 FY26 | −$0.14 | −$0.15 | −7.1% | — | — | — | +6.58% |
| Mar 12, 2026Q4 FY25 | −$0.14 | −$0.15 | −7.1% | $775.0K | — | — | −4.31% |
| Nov 4, 2025Q3 FY25 | −$0.14 | −$0.12 | +14.3% | — | — | — | −1.44% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | −$26.0K | −$29.0K | $0 | |
| Operating income | −$9.9M | −$10.3M | −$10.6M | −$12.2M | −$14.9M | −$19.3M | |
| Net income | $15.2M | −$8.0M | −$10.2M | −$12.3M | −$13.7M | −$18.0M | |
| Diluted EPS | −$0.13 | −$0.10 | −$0.12 | −$0.18 | −$0.15 | −$0.19 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $215.2M · Total debt $728.0K · Total assets $239.3M · Shareholders' equity $225.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 84.09M · Float 72.76M · 86.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Peter A. Thompson · director, 10 percent owner: | 7.20M | 8.56% | Form 4 | Jan 30, 2026 |
| Orbimed Advisors LLC | 7.17M | 8.52% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 7.14M | 8.49% | 13F | Aug 7, 2026 |
| Sirenia Capital Management LP | 6.83M | 7.50% | 13G | May 15, 2026 |
| State Street Corp | 4.47M | 5.32% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 11, 2026 | David Scott Moore | director | +21,700 | $11.53 |
| May 18, 2026 | Richard A. Md Miller | director, officer: President and CEO | +6,932 | $12.04 |
Peers
- Aclaris Therapeutics
Direct oral ITK/JAK3 peer in atopic dermatitis
- Innate Pharma (ADR)
Lacutamab targets CTCL and PTCL through KIR3DL2
- Regeneron
Dupixent sets the AD and asthma efficacy benchmark
- Citius Oncology
Commercial CTCL immunotherapy in the U.S.
- AbbVie
Oral JAK benchmark for moderate-to-severe AD
- Arcus Biosciences
CD73 and adenosine-pathway oncology peer
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals | $14.16 | +0.11% | $1.19B | — | — | — | — |
| Aclaris Therapeutics | $6.01 | 0.00% | $839.4M | — | — | 102.1 | −8.3% |
| Innate Pharma (ADR) | $2.22 | 0.00% | $208.5M | — | — | 63.2 | +1,574.1% |
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| Citius Oncology | $0.7756 | −1.50% | $72.1M | — | — | 10.1 | — |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Arcus Biosciences | $29.21 | +0.07% | $3.67B | — | — | 31.4 | −74.4% |
| Median | 45.8 | 15.0 | 20.8 | +10.2% |